ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.12-11

ImmunoPrecise Antibodies (NASDAQ:IPA) Second Quarter 2025 Results Key Financial Results Revenue: CA$6.13m (flat on 2Q 2024). Net loss: CA$2.55m (loss narrowed by 2.6% from 2Q 2024). CA$0.091 loss per...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490830144?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-12-11 18:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490830144","market":"us","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag","media":"Simply Wall St.","content":"<div>\n<p>ImmunoPrecise Antibodies (NASDAQ:IPA) Second Quarter 2025 Results\nKey Financial Results\n\nRevenue: CA$6.13m (flat on 2Q 2024).\nNet loss: CA$2.55m (loss narrowed by 2.6% from 2Q 2024).\nCA$0.091 loss per...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunoprecise-antibodies-second-quarter-2025-101735881.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 18:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immunoprecise-antibodies-second-quarter-2025-101735881.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunoPrecise Antibodies (NASDAQ:IPA) Second Quarter 2025 Results\nKey Financial Results\n\nRevenue: CA$6.13m (flat on 2Q 2024).\nNet loss: CA$2.55m (loss narrowed by 2.6% from 2Q 2024).\nCA$0.091 loss per...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunoprecise-antibodies-second-quarter-2025-101735881.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPA","symbol_name":"Immunoprecise Antibodies Ltd","start_time":0,"source_url":"https://finance.yahoo.com/news/immunoprecise-antibodies-second-quarter-2025-101735881.html","article_id":"2490830144","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490830144","pubTimestamp":1733912255,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGM:IPA Earnings and Revenue Growth December 11th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 4.9%. Earnings per share  exceeded analyst estimates by 8.3%.Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US.The company's shares are up 11% from a week ago.Be aware that  ImmunoPrecise Antibodies is showing  4 warning signs in our investment analysis and 1 of those is a bit unpleasant...","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IPA":"Immunoprecise Antibodies Ltd"},"translate_title":"ImmunoPrecise Antibodies 2025年第二季度收益：每股收益超出预期，收入滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies (NASDAQ:IPA) Second Quarter 2025 Results\nKey Financial Results\n\nRevenue: CA$6.13m (flat on 2Q 2024).\nNet loss: CA$2.55m (loss narrowed by 2.6% from 2Q 2024).\nCA$0.091 loss per share (improved from CA$0.10 loss in 2Q 2024).\n\n\n\n\n  NasdaqGM:IPA Earnings and Revenue Growth December 11th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nImmunoPrecise Antibodies EPS Beats Expectations, Revenues Fall Short\n Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) exceeded analyst estimates by 8.3%. \n Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. \nPerformance of the American Life Sciences industry.\n The company's shares are up 11% from a week ago. \nRisk Analysis\n Be aware that  ImmunoPrecise Antibodies is showing  4 warning signs in our investment analysis and 1 of those is a bit unpleasant... \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490830144"}